
Does Ozempic Cause Heart Problems, or Protect the Heart?
No: trials found fewer major heart events on Ozempic. What the label says about heart rate, palpitations and heart failure, and how Wegovy and Rybelsus differ.
Written by Dr. Sheri Tomas. Updated November 8, 2026.
No, the evidence does not show that Ozempic causes heart problems such as heart attacks or strokes; in the large trial behind its label, people on Ozempic had fewer major heart events than people on a placebo (a dummy treatment). Ozempic is the brand name for semaglutide injections given once a week to adults with type 2 diabetes. In the SUSTAIN-6 trial of 3,297 people with type 2 diabetes and heart disease or high heart risk, 6.6% of people on Ozempic had a heart attack, a stroke or died of heart disease over about two years, against 8.9% on placebo, a 26% lower risk. Because of that result, the FDA approved Ozempic to lower the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease. The one heart effect the label does report is a small rise in resting heart rate, on average 2 to 3 beats per minute. Below: the label, each trial, heart rate, palpitations, and how Ozempic, Rybelsus and Wegovy (all semaglutide, at different doses) differ.
Ozempic and Heart Health: The Short Answer
- 1Heart attacks and strokes: no increase; SUSTAIN-6 found 26% fewer major cardiovascular events with Ozempic.
- 2FDA status: Ozempic is approved to reduce major cardiovascular events in adults with type 2 diabetes and heart disease, and to reduce kidney decline and cardiovascular death in those with chronic kidney disease.
- 3Heart rate: the label reports an average rise of 2 to 3 beats per minute; there is no heart-rate warning on the Ozempic label.
- 4Heart rhythm: the label states semaglutide does not prolong the QT interval at doses up to 1.5 mg.
- 5Palpitations: not listed as a side effect on the Ozempic label, though dehydration or low blood sugar may cause them.
- 6Different products, different trials: Wegovy (2.4 mg) and Rybelsus (oral) have their own heart trials and labels.
Does Ozempic Cause Heart Problems?
Based on the trials and the FDA label, the answer is no for the outcomes that matter most. Diabetes drugs must show they do not raise the risk of heart attack, stroke and cardiovascular death, grouped as MACE (major adverse cardiovascular events). Ozempic did better: in SUSTAIN-6 it lowered MACE, and in a later kidney trial called FLOW it lowered cardiovascular death. Ozempic does raise resting heart rate slightly, and its side effects elsewhere in the body are covered in our guide to whether Ozempic is safe. This article focuses only on the heart. How the drug works in the first place is explained in how Ozempic works.
What Does the Ozempic Label Say About the Heart?
The current US prescribing information for Ozempic (revised May 2026) mentions the heart in four places:
- 1Indications: Ozempic is approved for blood sugar control in adults with type 2 diabetes; to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and to reduce the risk of sustained kidney decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
- 2Heart rate: in clinical trials, Ozempic 0.5 mg and 1 mg resulted in a mean increase in heart rate of 2 to 3 beats per minute, against a mean decrease of 0.3 beats per minute with placebo.
- 3Warnings: there is no heart-rate warning, and the label does not list arrhythmia, atrial fibrillation, palpitations or a fast heartbeat (tachycardia).
- 4Heart rhythm: semaglutide does not prolong the QTc interval, a measure on the ECG that some drugs lengthen, at doses up to 1.5 mg at steady state.
The cardiovascular indication was added in January 2020, a little over two years after Ozempic was first approved in December 2017. The kidney and cardiovascular death indication followed in January 2025. More on its main use is in Ozempic for diabetes.
What Did the SUSTAIN-6 Heart Trial Show?
SUSTAIN-6 compared Ozempic 0.5 mg or 1 mg with placebo in 3,297 adults with type 2 diabetes who had heart disease or were at high cardiovascular risk, for a median of 2.1 years. It was designed to rule out harm (non-inferiority) and went further, showing lower MACE. The label gives the parts:
SUSTAIN-6 results (Ozempic label, Section 14.2)
MACE (all three below combined)
6.6%
8.9%
0.74 (0.58 to 0.95)
Cardiovascular death
2.7%
2.8%
0.98 (0.65 to 1.48)
Nonfatal heart attack
2.9%
3.9%
0.74 (0.51 to 1.08)
Nonfatal stroke
1.6%
2.7%
0.61 (0.38 to 0.99)
A hazard ratio below 1 means fewer events with Ozempic; if the range in brackets (the 95% confidence interval) crosses 1, the difference could be due to chance. So the overall benefit was clear, the stroke reduction just significant, the heart attack reduction uncertain on its own, and cardiovascular death about equal. Some articles claim SUSTAIN-6 cut cardiovascular death by 26%; the 26% is for MACE as a whole. The same trial also found more diabetic eye (retinopathy) complications with Ozempic, 3.0% against 1.8%, worth knowing if you have diabetic eye disease.
Ozempic and Heart Attack: Does It Lower the Risk?
This is the honest answer: Ozempic does not raise heart attack risk, and it probably lowers it, but SUSTAIN-6 alone did not prove that. Nonfatal heart attacks were 2.9% with Ozempic and 3.9% with placebo, a hazard ratio of 0.74, but the confidence interval of 0.51 to 1.08 crosses 1.
A larger trial adds support. SOUL tested Rybelsus, the daily semaglutide tablet, at up to 14 mg in 9,650 people with type 2 diabetes and heart or kidney disease, followed for a median of almost four years. Major cardiovascular events fell from 13.8% to 12.0% (hazard ratio 0.86, or 14% lower), and the benefit came mainly from fewer nonfatal heart attacks. Those results apply to Rybelsus, not directly to Ozempic. The difference between the tablet and the injection is explained in Ozempic tablets and oral semaglutide. Ozempic does not replace statins, aspirin or blood pressure medicines after a heart attack.
Why Does Ozempic Raise Heart Rate, and Is It Dangerous?
A modest rise in resting pulse has been seen with semaglutide, and the label reports it without explaining the cause. For Ozempic, the label figure is an average rise of 2 to 3 beats per minute at 0.5 mg and 1 mg, which most people would not notice, though some individuals have larger rises.
Wegovy, which is semaglutide at a higher weekly dose of 2.4 mg for weight management, carries a heart-rate warning that Ozempic does not. Its label tells doctors to monitor heart rate, asks patients to report palpitations or a racing heartbeat at rest, and advises stopping Wegovy if the resting heart rate stays raised. That reflects Wegovy's higher dose and its own trial data. How the two compare more broadly is covered in Ozempic vs Wegovy.
Is a small rise in pulse harmful? The trials answer that indirectly. Despite the slightly higher heart rate, people on Ozempic had fewer heart attacks, strokes and cardiovascular deaths overall. A persistently fast pulse should still not be ignored.
Can Ozempic Cause Heart Palpitations?
Palpitations, the feeling that your heart is pounding, fluttering or skipping, are not listed as a side effect in the Ozempic label, and there is no trial figure for how often Ozempic users report them. Some people do describe them, and there are indirect ways Ozempic could contribute:
- 1Dehydration: nausea, vomiting and diarrhea are common early on and can lower fluid and salt levels, which can make the heart beat faster. See Ozempic and diarrhea.
- 2Low blood sugar: the risk of hypoglycemia is mainly an issue when Ozempic is combined with insulin or a sulfonylurea. A racing heart, shakiness and sweating are typical warning signs.
- 3Eating much less: skipping meals while appetite is suppressed can add to low blood sugar and light-headedness.
- 4Alcohol and caffeine: both can trigger palpitations and interact with low blood sugar; see Ozempic and alcohol.
- 5The small heart-rate rise itself, which some people may notice.
Palpitations can also come from thyroid problems, anemia, anxiety or a rhythm disorder. New or frequent palpitations are worth checking with your doctor, who may order an ECG.
What About Heart Failure?
Ozempic is not approved to treat heart failure, and its label does not list heart failure as a side effect. The most direct evidence comes from Wegovy, not Ozempic. STEP-HFpEF tested Wegovy 2.4 mg for 52 weeks in 529 people with obesity and heart failure with preserved ejection fraction (HFpEF, a type in which the heart pumps normally but is stiff). Symptom scores on a standard questionnaire improved by 16.6 points with Wegovy against 8.7 with placebo, weight fell by 13.3% against 2.6%, and walking distance in six minutes rose by 21.5 metres against 1.2 metres. In the SOUL trial of Rybelsus, 23% of participants had heart failure at the start. If you have heart failure, discuss any semaglutide product with your cardiologist.
How Do SOUL, SELECT and FLOW Fit In?
These trials are often lumped together as semaglutide, but they used different products, doses and populations:
Semaglutide heart trials by product
SUSTAIN-6
Ozempic 0.5 or 1 mg weekly injection
Type 2 diabetes plus heart disease or high risk
3,297
MACE 26% lower (HR 0.74)
FLOW
Ozempic 1 mg weekly injection
Type 2 diabetes plus chronic kidney disease
3,533
Kidney and heart composite 24% lower (HR 0.76); CV death HR 0.71
SOUL
Rybelsus up to 14 mg daily tablet
Type 2 diabetes plus heart or kidney disease
9,650
MACE 14% lower (HR 0.86)
SELECT
Wegovy 2.4 mg weekly injection
Heart disease and overweight, no diabetes
17,604
MACE 20% lower
STEP-HFpEF
Wegovy 2.4 mg weekly injection
HFpEF heart failure plus obesity
529
Symptom score +16.6 vs +8.7
FLOW deserves a closer look because it is an Ozempic trial. Over a median of 3.4 years, people with type 2 diabetes and kidney disease on Ozempic 1 mg had fewer kidney and heart outcomes, and cardiovascular deaths were 7.0% against 9.6% (hazard ratio 0.71). It was stopped early for benefit. Summaries also report fewer major cardiovascular events and deaths from any cause, but those figures are not in the label. Rybelsus gained its own cardiovascular indication from SOUL in October 2025, covering high-risk adults with type 2 diabetes with or without a previous heart event.
Does Ozempic Protect the Heart in People Without Diabetes?
Ozempic is not approved for people without type 2 diabetes, and none of its heart trials included them. The evidence in people without diabetes comes from SELECT, which tested Wegovy 2.4 mg in 17,604 adults aged 45 or older with established heart disease and a body mass index of 27 or higher. Major cardiovascular events were 20% lower with Wegovy. The reduction in cardiovascular death on its own (hazard ratio 0.85, 0.71 to 1.01) did not reach statistical confirmation. These results apply to Wegovy at its dose, not to Ozempic used off-label for weight loss; more on that distinction is in is Ozempic approved for weight loss. Any heart benefit also depends on staying on treatment, as covered in what happens when you stop Ozempic.
When to Talk to Your Doctor
Call emergency services right away for chest pain or pressure, fainting, severe shortness of breath, or signs of stroke such as face drooping, arm weakness or slurred speech. Contact your doctor promptly if you notice:
- 1A resting heart rate that stays fast, or a racing heart at rest that does not settle
- 2New, frequent or long-lasting palpitations, or palpitations with dizziness
- 3Shortness of breath when lying flat, or new swelling in your legs or ankles
- 4Shakiness, sweating and a fast heartbeat if you also take insulin or a sulfonylurea
- 5Vomiting or diarrhea that stops you keeping fluids down
- 6Changes in your vision, especially if you already have diabetic eye disease
What to Do Next: Questions to Ask Your Doctor
- 1Do I have established heart disease or kidney disease that makes Ozempic's cardiovascular indication relevant to me?
- 2Would Ozempic, Rybelsus or another option best fit my heart and kidney risk?
- 3Should my heart rate or an ECG be checked before or after starting?
- 4Do I need to adjust insulin or a sulfonylurea to avoid low blood sugar?
- 5How should I manage nausea and fluids to avoid dehydration?
- 6Should I have an eye exam because of the retinopathy finding in SUSTAIN-6?
Beyond heart attacks and strokes, many readers ask whether Ozempic changes blood pressure or cholesterol. Our guide does Ozempic lower blood pressure and cholesterol explains what trials show and why the Ozempic label has no data on either.
The Bottom Line
As of November 2026, the evidence shows that Ozempic does not cause heart attacks or strokes and lowers the overall risk of major cardiovascular events in adults with type 2 diabetes and heart disease, which is why the FDA approved it for that use. It raises resting heart rate by about 2 to 3 beats per minute on average, but the Ozempic label carries no heart-rate warning and reports no QT prolongation. Palpitations are not a listed side effect, though dehydration and low blood sugar can trigger them. Results from Rybelsus and Wegovy trials should not be read as Ozempic data.
FAQ
Yes, slightly. The Ozempic label reports an average rise of 2 to 3 beats per minute with the 0.5 mg and 1 mg doses, against a small decrease with placebo.
The trials do not show that. In SUSTAIN-6, nonfatal heart attacks were 2.9% with Ozempic against 3.9% with placebo, and major cardiovascular events overall were 26% lower.
For adults with type 2 diabetes and established heart disease, Ozempic is FDA approved to reduce the risk of major cardiovascular events.
Palpitations are not listed on the Ozempic label, but dehydration from stomach side effects or low blood sugar with insulin or a sulfonylurea can cause them. New or frequent palpitations should be checked by a doctor.
Ozempic is approved to reduce major cardiovascular events in adults with type 2 diabetes and established heart disease, and since January 2025 to reduce cardiovascular death and kidney decline in those with chronic kidney disease. It is not approved for heart disease in people without diabetes.
They are approved for different people. Ozempic's heart evidence is in type 2 diabetes; Wegovy's SELECT trial was in people with heart disease and overweight without diabetes. Wegovy's higher dose carries a heart-rate warning.
Sources
- 1Novo Nordisk. Ozempic (semaglutide) injection: US prescribing information, revised 05/2026, US Food and Drug Administration, 2026
- 2Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6), NEJM 2016; FDA approval of the cardiovascular indication, BioSpace, 2020
- 3Perkovic V et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW), NEJM 2024: summary, Diabetes on the Net, 2024
- 4FDA approves Ozempic to reduce kidney disease risk in patients with type 2 diabetes and chronic kidney disease, Pharmaceutical Executive, 2025
- 5McGuire DK et al. Oral semaglutide and cardiovascular outcomes in type 2 diabetes (SOUL), NEJM 2025: report, AJMC, 2025
- 6SOUL trial summary: oral semaglutide, Diabetes on the Net, 2025
- 7FDA approves oral semaglutide for cardiovascular risk reduction in adults with type 2 diabetes at high risk, BioSpace, 2025
- 8Lincoff AM et al. SELECT trial (NEJM 2023): Wegovy cardiovascular indication announcement, Novo Nordisk, 2024
- 9Kosiborod MN et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF), NEJM 2023: report, Pharmacy Times, 2023
This article summarizes published research and FDA labeling for general information and is not medical advice. The SUSTAIN-6, FLOW, SOUL, SELECT and STEP-HFpEF trials were funded by Novo Nordisk, the maker of Ozempic, Rybelsus and Wegovy.

Dr. Sheri Tomas
Author
Comments (0)
Be the first to comment on this article.




